SCHEMBL6135340

SCHEMBL6135340

CCCSc1nccc(O)n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
MAPT P10636 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
HASPIN Q8TF76 2/20 0.40
KMT2A Q03164 1/20 0.39
APLNR P35414 3/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 1/20 0.37
KDM4E B2RXH2 3/20 0.36
NPSR1 Q6W5P4 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA1 P30542 1/20 0.35
ALPL P05186 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7022821 0.86 GPR84 (0.47) HPGDNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL17371365 0.79 ALOX15 (0.57) HPGDNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL25239244 0.78 HASPIN (0.46) HPGDNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL14834735 0.78 KMT2A (0.41) HPGDNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL12656989 0.78 NPC1 (0.40) HPGDNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL16920981 0.77 ALDH1A1 (0.47) HPGDNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL2558503 0.76 ALOX15 (0.39) HPGDNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL1253257 0.76 ALDH1A1 (0.45) HPGDSMN1; SMN2APLNRALDH1A1LMNA
SCHEMBL5928189 0.75 ALDH1A1 (0.33) HPGDALOX15KMT2AALDH1A1NPSR1
SCHEMBL12744426 0.75 ALOX15 (0.36) HPGDNPC1RAB9ASMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1385830-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-08-17 EP disclosed
US-20040152895-A1 Sulfonamides SMITHKLINE BEECHAM CORPORATION 2004-08-05 US disclosed
EP-1385830-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP disclosed
WO-2002090337-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152895-A1 Sulfonamides UTS2R, PRSS2, STS HPGD 1890/4885NPC1 3410/4885RAB9A 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.